Renzaprid

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
Renzaprid
(IUPAC) ime
4-amino-N-[(4S,5S)-1-azabiciklo[3.3.1]non-4-il]-5-hloro-2-metoksibenzamid
Klinički podaci
Identifikatori
CAS broj 109872-41-5
ATC kod nije dodeljen
PubChem[1][2] 3086547
ChemSpider[3] 16736758
UNII 9073C0W4E9 YesY
ChEMBL[4] CHEMBL289753 YesY
Hemijski podaci
Formula C16H22ClN3O2 
Mol. masa 323,818 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status

Renzaprid je gastroprokinetički agens i antiemetik koji deluje kao pun 5-HT4 pun agonist i 5-HT3 antagonist.[5][6] On takođe funkcioniše kao 5-HT2B antagonist i ima isti afinitet za 5-HT2A i 5-HT2C receptore, mada je malo verovatno da oni doprinose njegovom terapeutskom dejstvu.[5]

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3.  edit
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  5. 5,0 5,1 Meyers NL, Hickling RI. (2008). „Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.”. Drugs R D. 9 (1): 37–63. PMID 18095752. 
  6. Camilleri M., McKinzie S., Fox J., Foxx-Orenstein A., Burton D., Thomforde G., Baxter K. and Zinsmeister A. R. (2004). "Effect of Renzapride on Transit in Constipation-Predominant Irritable Bowel Syndrome", Clin. Gastroent. and Hepatology; 2:895-904

Spoljašnje veze[uredi - уреди | uredi izvor]